+ Include: 3 videos + 1 pdf, size: 33.69 GB
+ Target Audience: professionals in drug discovery, who focus on oligonucleotide, peptide, mRNA, and genome editing therapeutics
+ Information:
A translational, end-to-end program covering discovery, delivery, CMC, analytics, manufacturing, and clinical development for oligonucleotide and peptide drugs. Sessions convert cutting-edge science into practical playbooks for moving candidates efficiently from idea to IND and through the clinic.
What You Will Learn
-
Platform selection & design: ASO/siRNA/miRNA/mRNA/saRNA vs. peptides/peptidomimetics—chemistries, stability, and manufacturability
-
Delivery strategies: LNPs, GALNAc, conjugates, depot and targeted systems; PK/PD and biodistribution considerations
-
CMC & analytics: impurity control, sequence confirmation, potency/stability assays, comparability, and QbD
-
Process development & scale-up: solid-phase/liquid-phase synthesis, hybrid approaches, purification and formulation
-
Regulatory & quality: IND/IMPD expectations, ICH alignment, control strategies, and lifecycle management
-
Nonclinical & clinical translation: models, safety/pharm-tox, biomarkers, dose selection, trial design
-
Operations: raw-material sourcing, supply chain resilience, technology transfer, and cost-of-goods levers
-
Data & digital: sequence optimization, structure prediction, in-silico off-target analysis, and AI/automation in analytics
Event Details
-
Format: Plenary talks, parallel technical tracks, case studies, panels, posters, and exhibits
-
Structure: Discovery/design → Delivery/PKPD → CMC/analytics → Manufacturing/scale-up → Clinical/regulatory → Commercialization
-
Takeaways: Checklists, templates, and benchmark metrics for immediate team adoption
Who Should Attend
R&D scientists, CMC and QA/QC leaders, process/analytical chemists, formulation and delivery engineers, clinical and regulatory teams, manufacturing/operations managers, BD and strategy leaders, platform founders, and investors.
Why Attend
-
Replace trial-and-error with validated development pathways for RNA and peptide modalities
-
Anticipate regulatory and manufacturing pitfalls early to de-risk timelines and budgets
-
Build partnerships across discovery, CMC, and clinical teams to accelerate to proof-of-concept
+ Topics:
Reviews
There are no reviews yet.